Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment
Fuente:
Redalyc
Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Medical Education Cooperation with Cuba
2021
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1876470337850310656 |
|---|---|
| author | Haslen H. Cáceres-Lavernia |
| author_facet | Haslen H. Cáceres-Lavernia |
| contents | Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment Haslen H. Cáceres-Lavernia Elia Nenínger-Vinageras Leslie M. Varona-Rodríguez Yoli A. Olivares-Romero Irlis Sánchez-Rojas Zaima Mazorra-Herrera Denenke Basanta-Bergolla Dayanis Duvergel-Calderín Boris L. Torres-Cuevas Concepción del Castillo-Carrillo Medicina non Cuba carcinoma Racotumomab lung neoplasms INTRODUCTION Racotumomab is a therapeutic vaccine based on a monoclonal anti-idiotypic antibody developed by the Molecular Immunology Center in Havana, Cuba, that is registered in Cuba and Argentina for treatment of non-small cell lung cancer. It induces a specific humoral and cellular immune response against the N-glycolyl GM3 (NeuGcGM3) ganglioside present in tumor cells, thereby provoking the death of these cells.OBJECTIVE Evaluate racotumomab vaccine use as switch maintenance and second-line therapy for patients with inoperable non-small cell lung cancer in routine clinical practice, outside the framework of clinical studies, and assess the overall survival, stage-specific survival and safety in these patients.METHODS A descriptive, retrospective study was carried out in patients diagnosed with non-small cell lung cancer not suitable for surgical treatment, who received racotumomab as a part of switch maintenance or second-line treatments. Overall survival was defined from diagnosis and from the first immunization, until death.RESULTS We included 71 patients treated with racotumomab, 57.7% (41/71) of whom were in stages IIIB and IV of non-small cell lung cancer. Of the patients, 84.5% (60/71) had no adverse events, and 15.5% (11/71) had mild adverse reactions. The median overall survival was 24.5 months, calculated from the first immunization, 17.2 months for those who received racotumomab as switch maintenance and 6.8 months for patients who had progressed after the first line of treatment.CONCLUSIONS Racotumomab in routine clinical practice prolonged overall survival in patients with non-small cell lung cancer treated in switch maintenance, and in stage IV patients who received the treatment as second-line therapy. The vaccine was well tolerated. 2021 artículo científico 1555-7960 https://www.redalyc.org/articulo.oa?id=437571586005 https://www.redalyc.org/journal/4375/437571586005/ https://www.redalyc.org/journal/4375/437571586005/html/ https://www.redalyc.org/journal/4375/437571586005/437571586005.epub https://www.redalyc.org/journal/4375/437571586005/movil https://doi.org/10.37757/mr2021.v23.n3.5 en http://www.redalyc.org/revista.oa?id=4375 MEDICC Review application/pdf Medical Education Cooperation with Cuba MEDICC Review (Estados Unidos de América) Num.3-4 Vol.23 |
| format | Artículo científico |
| id | redalyc_437571586005 |
| institution | Redalyc |
| language | en |
| publishDate | 2021 |
| publisher | Medical Education Cooperation with Cuba |
| spellingShingle | Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment Haslen H. Cáceres-Lavernia Medicina non Cuba carcinoma Racotumomab lung neoplasms Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment Haslen H. Cáceres-Lavernia Elia Nenínger-Vinageras Leslie M. Varona-Rodríguez Yoli A. Olivares-Romero Irlis Sánchez-Rojas Zaima Mazorra-Herrera Denenke Basanta-Bergolla Dayanis Duvergel-Calderín Boris L. Torres-Cuevas Concepción del Castillo-Carrillo Medicina non Cuba carcinoma Racotumomab lung neoplasms INTRODUCTION Racotumomab is a therapeutic vaccine based on a monoclonal anti-idiotypic antibody developed by the Molecular Immunology Center in Havana, Cuba, that is registered in Cuba and Argentina for treatment of non-small cell lung cancer. It induces a specific humoral and cellular immune response against the N-glycolyl GM3 (NeuGcGM3) ganglioside present in tumor cells, thereby provoking the death of these cells.OBJECTIVE Evaluate racotumomab vaccine use as switch maintenance and second-line therapy for patients with inoperable non-small cell lung cancer in routine clinical practice, outside the framework of clinical studies, and assess the overall survival, stage-specific survival and safety in these patients.METHODS A descriptive, retrospective study was carried out in patients diagnosed with non-small cell lung cancer not suitable for surgical treatment, who received racotumomab as a part of switch maintenance or second-line treatments. Overall survival was defined from diagnosis and from the first immunization, until death.RESULTS We included 71 patients treated with racotumomab, 57.7% (41/71) of whom were in stages IIIB and IV of non-small cell lung cancer. Of the patients, 84.5% (60/71) had no adverse events, and 15.5% (11/71) had mild adverse reactions. The median overall survival was 24.5 months, calculated from the first immunization, 17.2 months for those who received racotumomab as switch maintenance and 6.8 months for patients who had progressed after the first line of treatment.CONCLUSIONS Racotumomab in routine clinical practice prolonged overall survival in patients with non-small cell lung cancer treated in switch maintenance, and in stage IV patients who received the treatment as second-line therapy. The vaccine was well tolerated. 2021 artículo científico 1555-7960 https://www.redalyc.org/articulo.oa?id=437571586005 https://www.redalyc.org/journal/4375/437571586005/ https://www.redalyc.org/journal/4375/437571586005/html/ https://www.redalyc.org/journal/4375/437571586005/437571586005.epub https://www.redalyc.org/journal/4375/437571586005/movil https://doi.org/10.37757/mr2021.v23.n3.5 en http://www.redalyc.org/revista.oa?id=4375 MEDICC Review application/pdf Medical Education Cooperation with Cuba MEDICC Review (Estados Unidos de América) Num.3-4 Vol.23 |
| title | Racotumomab in Non-Small Cell Lung Cancer as Maintenance and Second-Line Treatment |
| topic | Medicina non Cuba carcinoma Racotumomab lung neoplasms |
| url | https://www.redalyc.org/articulo.oa?id=437571586005 https://www.redalyc.org/journal/4375/437571586005/ https://www.redalyc.org/journal/4375/437571586005/html/ https://www.redalyc.org/journal/4375/437571586005/437571586005.epub https://www.redalyc.org/journal/4375/437571586005/movil https://doi.org/10.37757/mr2021.v23.n3.5 |